Lipoprotein clearance mechanisms in LDL receptor-deficient 'apo-B48- only' and 'apo-B100-only' mice

Journal of Clinical Investigation

Volumn 102, Issue 8, 1998, Pages 1559-1568

  Véniant, Murielle M ^a,b   Zlot, Constance H ^a   Walzem, Rosemary L ^d   Pierotti, Vincenzo ^a   Driscoll, Robert ^a   Dichek, David ^a,b,c   Herz, Joachim ^e   Young, Stephen G ^a,b,c  

^a GLADSTONE INSTITUTE OF CARDIOVASCULAR DISEASE   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d UNIVERSITY OF CALIFORNIA   (United States)

^e UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

Author keywords

Adenovirus mediated gene transfer; LDL receptor deficiency; LDL receptor related protein; Low density lipoproteins; Mouse apo B radioimmunoassay

Indexed keywords

APOLIPOPROTEIN B100; APOLIPOPROTEIN B48; LIPOPROTEIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN RECEPTOR;

ANIMAL EXPERIMENT; ARTICLE; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; FAMILIAL HYPERCHOLESTEROLEMIA; GENE TRANSFER; LIPID TRANSPORT; LIPOPROTEIN BLOOD LEVEL; LIPOPROTEIN METABOLISM; MOUSE; NONHUMAN; PRIORITY JOURNAL;

EID: 0032532670     PISSN: 00219738     EISSN: None     Source Type: Journal    
DOI: 10.1172/JCI4164     Document Type: Article

References (35)

1. Havel, R.J., and J.P. Kane. 1995. Introduction: structure and metabolism of plasma lipoproteins. In The Metabolic and Molecular Bases of Inherited Disease, 7th ed., Vol. 2. C.R. Scriver, A.L. Beaudet, W.S. Sly, and D. Valle, editors. McGraw-Hill, New York. 1841-1851.
2. Young, S.G. 1990. Recent progress in understanding apolipoprotein B. Circulation. 82:1574-1594.
3. Kane, J.P. 1983. Apolipoprotein B: structural and metabolic heterogeneity. Annu. Rev. Physiol. 45:637-650.
4. Davidson, N.O., S. Anant, and A.J. MacGinnitie. 1995. Apolipoprotein B messenger RNA editing: insights into the molecular regulation of post-transcriptional cytidine deamination. Curr. Opin. Lipidol. 6:70-74.
5. Greeve, J., I. Altkemper, J.-H. Dieterich, H. Greten, and E. Windler. 1993. Apolipoprotein B mRNA editing in 12 different mammalian species: hepatic expression is reflected in low concentrations of apoB-containing plasma lipoproteins. J. Lipid Res. 34:1367-1383.
6. Purcell-Huynh, D.A., R.V. Farese, Jr., D.F. Johnson, L.M. Flynn, V. Pierotti, D.L. Newland, M.F. Linton, D.A. Sanan, and S.G. Young. 1995. Transgenic mice expressing high levels of human apolipoprotein B develop severe atherosclerotic lesions in response to a high-fat diet. J. Clin. Invest. 95:2246-2257.
7. Goldstein, J.L., and M.S. Brown. 1989. Familial hypercholesterolemia. In The Metabolic Basis of Inherited Disease, 6th ed., C.R. Scriver, A.L. Beaudet, W.S. Sly, and D. Valle, editors. McGraw-Hill, New York. 1215-1250.
8. Marcel, Y.L., T.L. Innerarity, C. Spilman, R.W. Mahley, A.A. Protter, and R.W. Milne. 1987. Mapping of human apolipoprotein B antigenic determinants. Arteriosclerosis. 7:166-175.
9. Milne, R.W., P.K. Weech, L. Blanchette, J. Davignon, P. Alaupovic, and Y.L. Marcel. 1984. Isolation and characterization of apolipoprotein B-48 and B-100 very low density lipoproteins from type III hyperlipoproteinemic subjects. J. Clin. Invest. 73:816-823.
10. Mahley, R.W. 1988. Apolipoprotein E: cholesterol transport protein with expanding role in cell biology. Science. 240:622-630.
11. Ishibashi, S., J. Herz, N. Maeda, J.L. Goldstein, and M.S. Brown. 1994. The two-receptor model of lipoprotein clearance: tests of the hypothesis in "knockout" mice lacking the low density lipoprotein receptor, apolipoprolein E, or both proteins. Proc. Natl. Acad. Sci. USA. 91:4431-4435.
12. Willnow, T.E., Z. Sheng, S. Ishibashi, and J. Herz. 1994. Inhibition of hepatic chylomicron remnant uptake by gene transfer of a receptor antagonist. Science. 264:1471-1474.
13. Rohlmann, A., M. Gotthardt, R.E. Hammer, and J. Herz. 1998. Inducible inactivation of hepatic LRP gene by Cre-mediated recombination confirms role of LRP in clearance of chylomicron remnants. J. Clin. Invest. 101:689-695.
14. Farese, R.V., Jr., M.M. Véniant, C.M. Cham, L.M. Flynn, V. Pierotti, J.F. Loring, M. Traber, S. Ruland, R.S. Stokowski, D. Huszar, et al. 1996. Phenotypic analysis of mice expressing exclusively apolipoprotein B48 or apolipoprotein B100. Proc. Natl. Acad. Sci. USA. 93:6393-6398.
15. Ishibashi, S., M.S. Brown, J.L. Goldstein, R.D. Gerard, R.E. Hammer, and J. Herz. 1993. Hypercholesterolemia in low density lipoprotein receptor knockout mice and its reversal by adenovirus-mediated gene delivery. J. Clin. Invest. 92:883-893.
16. Véniant, M.M., V. Pierotti, D. Newland, C.M. Cham, D.A. Sanan, R.L. Walzem, and S.G. Young. 1997. Susceptibility to atherosclerosis in mice expressing exclusively apolipoprotein B48 or apolipoprotein B100. J. Clin. Invest. 100:180-188.
17. Walzem, R.L., P.A. Davis, and R.J. Hansen. 1994. Overfeeding increases very low density lipoprotein diameter and causes the appearance of a unique lipoprotein particle in association with failed yolk deposition. J. Lipid Res. 35:1354-1366.
18. Kirn, E., C.M. Cham, M.M. Véniant, P. Ambroziak, and S.G. Young. 1998. Dual mechanisms for the low plasma levels of truncated apolipoprotein B proteins in familial hypobetalipoproteinemia. Analysis of a new mouse model with a nonsense mutation in the Apob gene. J. Clin. Invest. 101:1468-1477.
19. Raabe, M., L.M. Flynn. C.F. Zlot, J.S. Wong, M. Véniant, R.L. Hamilton, and S.G. Young. 1998. Knockout of the abetalipoproteinemia gene in mice: reduced lipoprotein secretion in heterozygotes and embryonic lethality in homozygotes. Proc. Natl. Acad. Sci. USA. 95:8686-8691.
20. Dong, G., A.H. Schulick, M.B. DeYoung, and D.A. Dichek. 1996. Identification of a cis-acting sequence in the human plasminogen activator inhibitor type-1 gene that mediates transforming growth factor-β1 responsiveness in endothelium in vivo. J. Biol. Chem. 271:29969-29977.
21. Linton, M.F., R.V. Farese, Jr., G. Chiesa, D.S. Grass, P. Chin, R.E. Hammer, H.H. Hobbs, and S.G. Young. 1993. Transgenic mice expressing high plasma concentrations of human apolipoprotein B100 and lipoprotein(a). J. Clin. Invest. 92:3029-3037.
22. Kim, E., and S.G. Young. 1998. Genetically modified mice for the study of apolipoprotein B. J. Lipid Res. 39:703-723.
23. Mokuno, H., S. Brady, L. Kotite, J. Herz, and R.J. Havel. 1994. Effect of the 39-kDa receptor-associated protein on the hepatic uptake and endocytosis of chylomicron remnants and low density lipoproteins in the rat. J. Biol. Chem. 269:13238-13243.
24. Bu, G. 1998. Receptor-associated protein: a specialized chaperone and antagonist for members of the LDL receptor gene family. Curr. Opin. Lipidol. 9:149-155.
25. Goldstein, J.L., M.S. Brown, R.G.W. Andersen, D.W. Russell, and W.J. Schneider. 1985. Receptor-mediated endocytosis: concepts emerging from the LDL receptor system. Annu. Rev. Cell Biol. 1:1-39.
26. Willnow, T.E., S.A. Armstrong, R.E. Hammer, and J. Herz. 1995. Functional expression of low density lipoprotein receptor-related protein is controlled by receptor-associated protein in vivo. Proc. Natl. Acad. Sci. USA. 92: 4537-4541.
27. Schneeman, B.O., L. Kotite, K.M. Todd, and R.J. Havel. 1993. Relationships between the responses of triglyceride-rich lipoproteins in blood plasma containing apolipoproteins B-48 and B-100 to a fat-containing meal in normolipidemic humans. Proc. Natl. Acad. Sci. USA. 90:2069-2073.
28. Beisiegel, U., W. Weber, G. Ihrke, J. Herz, and K.K. Stanley. 1989. The LDL-receptor-related protein, LRP, is an apolipoprotein E-binding protein. Nature. 341:162-164.
29. Kowal, R.C., J. Herz, J.L. Goldstein, V. Esser, and M.S. Brown. 1989. Low density lipoprotein receptor-related protein mediates uptake of cholesteryl esters derived from apoprotein E-enriched lipoproteins. Proc. Natl. Acad. Sci. USA. 86:5810-5814.
30. Linton, M.F., A.H. Hasty, V.R. Babaev, and S. Fazio. 1998. Hepatic apo E expression is required for remnant lipoprotein clearance in the absence of the low density lipoprotein receptor. J. Clin. Invest. 101:1726-1736.
31. Mahley, R.W. 1996. Heparan sulfate proteoglycan/low density lipoprotein receptor-related protein pathway involved in type III hyperlipoproteinemia and Alzheimer's disease. Isr. J. Med. Sci. 32:414-429.
32. Ishibashi, S., S. Perrey, Z. Chen, J.-I. Osuga, M. Shimada, K. Ohashi, K. Harada, Y. Yazaki, and N. Yamada. 1996. Role of the low density lipoprotein (LDL) receptor pathway in the metabolism of chylomicron remnants. A quantitative study in knockout mice lacking the LDL receptor, apolipoprotein E, or both. J. Biol. Chem. 271:22422-22427.
33. Tsukamoto, K., P. Smith, J.M. Glick, and D.J. Rader. 1997. Liver-directed gene transfer and prolonged expression of three major human apoE isoforms in apoE-deficient mice. J. Clin. Invest. 100:107-114.
34. Ishibashi, S., J.L. Goldstein, M.S. Brown, J. Herz, and D.K. Burns. 1994. Massive xanthomatosis and atherosclerosis in cholesterol-fed low density lipoprotein receptor-negative mice. J. Clin. Invest. 93:1885-1893.
35. Powell-Braxton, L., M. Véniant, R.D. Latvala, K.-I. Hirano, W.B. Won, J. Ross, N. Dybdal, C.H. Zlot, S.G. Young, and N.O. Davidson. 1998. A mouse model of human familial hypercholesterolemia: markedly elevated low density lipoprotein cholesterol levels and severe atherosclerosis on a low-fat, chow diet. Nat. Med. 4:934-938.